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Abstract
Purpose: VEGF-targeted therapies have modest efficacy in
cancer patients, but acquired resistance is common. The mechan-
isms underlying such resistance are poorly understood.
Experimental Design: To evaluate the potential role of
immune cells in the development of resistance to VEGF block-
ade, we first established a preclinical model of adaptive resis-
tance to anti-VEGF therapy. Additional in vitro and in vivo
studies were carried out to characterize the role of macrophages
in such resistance.
Results: Using murine cancer models of adaptive resistance to
anti-VEGF antibody (AVA), we found a previously unrecognized
role ofmacrophages in such resistance.Macrophageswere actively
recruited to the tumor microenvironment and were responsible
for the emergence of AVA resistance. Depletion of macrophages
following emergence of resistance halted tumor growth and
prolonged survival of tumor-bearing mice. In a macrophage-
deficient mouse model, resistance to AVA failed to develop, but
could be induced by injection of macrophages. Downregulation
of macrophage VEGFR-1 and VEGFR-3 expression accompanied
upregulation of alternative angiogenic pathways, facilitating
escape from anti-VEGF therapy.
Conclusions: These findings provide a new understanding of
the mechanisms underlying the modest efficacy of current anti-
angiogenesis therapies and identify new opportunities for com-
bination approaches for ovarian and other cancers. Clin Cancer Res;
23(22); 7034–46. 2017 AACR.
Introduction
Angiogenesis is a hallmark of cancer and is essential for
tumor growth and metastasis (1). Of the complex mechan-
isms regulating blood vessel formation in cancer, the VEGF
family and associated receptors are recognized as a dominant
pathway (2). VEGF (VEGF-A) exerts its effects largely through
VEGF receptor (VEGFR)-2 and acts as the central promoter of
tumor angiogenesis (3). As VEGF is constitutively overex-
pressed in many cancers, therapies targeting this pathway
were highly anticipated additions to standard chemothera-
peutic drugs (4). Yet, clinical survival benefits from antian-
giogenic therapies have been modest (5); resistance to these
agents often emerges, and tumor growth resumes, along with
rapid revascularization following termination of these thera-
pies (6, 7). Indeed, several clinical trials show the collapse of
survival curves and clinical benefit following cessation of
therapy with antiangiogenic agents such as bevacizumab
(8–10). The mechanisms responsible for these clinical phe-
nomena remain unclear; however, possible avenues for escape
from VEGF blockade lie in the stromal components of the
tumor microenvironment.
Populations of macrophages express Tie2 and are capable of
vascular mimicry through the expression of endothelial cell
markers and the formation of capillary-like structures in
response to VEGF, possibly paving the way for vessel matura-
tion with replacement by true endothelial cells (11). It is
already reported that inherent anti-VEGF refractoriness is asso-
ciated with infiltration of the tumor tissue by CD11bþGr1þ
myeloid cells (12). Furthermore, macrophages have been
implicated in the development of resistance to antitumor
therapies, including platinum-based chemotherapy and
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radiotherapy (13–15). Through their ability to induce proan-
giogenic pathways, macrophages may play important roles in
resistance to drugs targeting the VEGF/VEGFR pathways (16).
To identify potentialmechanisms of adaptive resistance to anti-
VEGF therapy, we carried out a series of in vitro and in vivo
experiments and found that macrophages actively contribute to
resistance to anti-VEGF therapy. Importantly, we demonstrate a
previously unrecognized ability of macrophages to adapt to anti-
VEGF therapies through modulation of VEGFR expression and
other proangiogenic factors.
Materials and Methods
Cell lines and tissue culture
IG10 cells were maintained in DMEM supplemented with
5% FBS, 1x insulin-transferrin-sodium selenite supplement
(Roche Diagnostics), and 0.1% gentamicin sulfate (Gemini
Bio Products). OVCAR5 cells were maintained in DMEM with
10% FBS and 0.1% gentamicin sulfate. SKOV3ip1 cells were
maintained in RPMI 1640 medium supplemented with 15%
FBS and 0.1% gentamicin sulfate. All cell lines were validated
by short tandem repeat fingerprinting and were routinely
screened for mycoplasma. Experiments were performed at
60% to 80% cell confluence.
Immortomouse macrophages
Immortomouse macrophages, a kind gift from Dr. Robert
Langley, were maintained in DMEM with 10% FBS and 0.1%
gentamicin sulfate. These conditionally immortalized cells are
derived from the Immortomouse (The Jackson Laboratory) and
bear a transgene that allows interferon-inducible expression of a
thermolabile large tumor antigen (and the small tumor antigen)
from the SV40 thermosensitive A58 strain directed to widespread
tissues by the IFN-inducible Class I antigen promoter from the
mouse H-2Kb locus. The gene product of the thermolabile large
tumor antigen from the SV40 thermosensitive A58 strain is
functional at 33C but is rapidly degraded at 39.5C (17, 18).
Thus, immortomouse macrophages could be cultured at 33C,
where they proliferate as an immortalized cell line, but fail to
proliferate after incubation at 39.5C.
Animal studies
All animal work was done in accordance with protocols
approved by the Institutional Animal Care and Use Committee
at The University of Texas MD Anderson Cancer Center. Female
athymic nude mice and immune-competent (C57BL/6) mice
were purchased from the Animal Production Area of the National
Cancer Institute's Frederick Cancer Research and Development
Center (Frederick, MD). Homozygous B6.Cg-Csflr (tmlJwp)/J
mice were obtained from The Jackson Laboratory. GFP-
labeled FVB.Cg-Tg (CAG-EGFP) B5Nagy/J mice, a kind gift from
Dr. Michael Andreeff, served as donors for bone marrow trans-
plants. All animals were cared for in accordance with the guide-
lines set forth by the Association for Assessment andAccreditation
of Laboratory Animal Care International and the U.S. Public
Health Service Policy on Humane Care and Use. All animals used
were 8 to 12 weeks old at the time of injection.
Statistical analysis
A P value of <0.05 was considered statistically significant. We
used the Mann–Whitney U test (nonparametric) to compare
unmatched groups of values corresponding to xenograft tumor
volumes or luminescence signals and tissue protein expression.
Differences in apoptosis were analyzed via an unpaired t test
comparing the means of two groups of values. We used a Fisher
exact test to compare the incidence of metastasis between treat-
ment groups and controls.
Bone marrow transplant
Recipient C57BL/6 mice received 1,000 cGy of radiation and
underwent bone marrow transplantation intravenously within
24 hours. Bone marrow from FVB.Cg-Tg(CAG-EGFP)B5Nagy/J
mice was harvested, subjected to fluorescence-activated cell
sorting to isolate GFP-high expressing cells, suspended in
Hank's balanced salt solution (Gibco), and injected into recip-
ient mice. Recipient mice recuperated for 21 days, and then
successful transplantation was confirmed by hematologic pro-
filing, including verification of GFP-labeled bone marrow–
derived cells.
In vivo model of ovarian cancer and tissue processing
For all animal experiments, cells were harvested using tryp-
sin–ethylenediaminetetraacetic acid (EDTA), neutralized with
FBS-containing media, washed, and resuspended to the appro-
priate cell number in Hank's balanced salt solution prior to
injection. For CSF1R–/– mice, IG10 cells (1.25  106) were
injected intraperitoneally. IG10 (1  106) and OVCAR5 (1 
106) cells were transduced with lentivirus-encoding luciferase
and injected into C57BL/6 mice and nude mice, respectively.
Mice were imaged once weekly for luminescent signals using
a Xenogen IVIS system (Xenogen Corp.). For macrophage
infusion, immortomouse macrophages were harvested using
trypsin-EDTA, neutralized with FBS-containing media, washed,
and resuspended to the appropriate cell number in Hank's
balanced salt solution prior to injection of 50 mL intravenously.
For syngeneic mouse models, the B20 antibody was adminis-
tered intraperitoneally at 5 mg/kg twice per week. For nude
mouse models, bevacizumab was given intraperitoneally at
6.25 mg/kg twice per week. Zoledronic acid was given intra-
peritoneally at 1 mg/kg once per week. At the time of necropsy,
the weight, number, and distribution of tumors were recorded.
Individuals who performed necropsies were blinded to the
treatment group assignments. Tissue specimens were fixed with
either formalin or optimal cutting temperature compound
(Miles Laboratories) or were snap frozen in liquid nitrogen.
Translational Relevance
Although anti-VEGF antibody has provided clinical ben-
efit for cancer patients, adaptive resistance develops rapidly
in most, limiting its utility. We found that macrophages in
the tumor microenvironment orchestrate anti-VEGF therapy
resistance. At the emergence of resistance, depletion of
macrophage VEGFR-1 and VEGFR-3 expression accompa-
nies upregulation of alternative angiogenic pathways, facil-
itating escape from anti-VEGF therapy. Macrophage deple-
tion could be used to improve the effectiveness of VEGF
blockade in the treatment of cancer patients. These findings
have significant implications for clinical management of
cancer patients.
Macrophages Adapt to Anti-VEGF Therapy
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Quantitative real-time PCR
The total RNA from either cell lines or tumor tissue was
extracted using a QIAGEN RNeasy kit. With 1 mg of RNA, cDNA
was synthesized using a Verso cDNA kit (Thermo Scientific) per
the manufacturer's instructions. cDNA was then subjected to
amplification by real-time PCR using specific primer sequences
(100 ng/mL) as specified in Supplementary Table S1. For real-time
reverse transcription PCR, we obtained quantitative values (each
sample was normalized on the basis of its 18S content) as
previously described (19).
Methylation-specific PCR
MethPrimer software (http://www.urogene.org/methpri
mer/) was used for the prediction of the CpG islands of the
VEGFR-1 and VEGFR-3 promoter regions and for design of
methylation-specific primers (Supplementary Table S1). Total
DNA was isolated from control, B20-sensitive, and B20-resis-
tant Immortomouse macrophage cells using phenol:chloro-
form extraction, followed by treatment with bisulfite using a
methylation kit (EZ DNA Methylation-Gold; Zymo Research).
With the use of real-time PCR as described above, quantifica-
tion of methylation in B20-resistant and -sensitive samples was
performed and compared.
Gene expression microarray
Immortalized murine macrophages were treated with B20
for 2 weeks (sensitive) or 6 weeks (resistant), and then RNA
was extracted using the mirVana RNA isolation labeling Kit
(Ambion). Five hundred nanograms of total RNA were used for
labeling and hybridization on a Murine Wg-6 v2 Beadchip
(Illumina) according to the manufacturer's protocol. After the
bead chips were scanned with an Illumina BeadArray Reader
(Illumina), the microarray data were normalized using the
quantile normalization method in the Linear Models for Micro-
array Data package in the R language environment. The expres-
sion level of each gene was transformed into a log2 base before
further analysis.
Reverse phase protein arrays
Immortalized murine macrophages were treated with B20
for 2 weeks (sensitive) or 6 weeks (resistant). Cells were har-
vested at 80% confluence and lysed in modified radioimmu-
noprecipitation assay buffer (50 mmol/L Tris, 150 mmol/L
NaCl, 1% Triton X-100, 0.5% deoxycholate, 25 mg/mL leu-
peptin, 10 mg/mL aprotinin, 2 mmol/L EDTA, and 1 mmol/L
sodium orthovanadate). Reverse phase protein array (RPPA)
analysis was performed at the MD Anderson Cancer Center
Functional Proteomics RPPA Core Facility using the methods
described at the following web address: http://www.mdanderson.
org/education-and-research/resources-for-professionals/scientific-
resources/core-facilities-and-services/functional-proteomics-rppa-
core/index.html. Samples were probed with 161 antibodies by a
catalyzed signal amplification approach and visualized by 3,30-
diaminobenzidine chromogen colorimetric reaction. Slides were
scanned on a flatbed scanner to produce a 16-bit TIFF image. Spots
from TIFF images were identified, and the density was quantified
by MicroVigene (VigeneTech). Relative protein levels for each
sample were determined by interpolation of each dilution's curves
from the "standard curve" (supercurve) of the slide (antibody). All
data presented are in fold change compared with the baseline
(control treatment). Positive fold change was calculated by divid-
ingeach linear value (>1.0)with theaverage control linear value for
each antibody tested, whereas negative fold change (for linear
values < 1.0) was also calculated (using the following formula: –1/
linear fold change) as in log 2.0 value.
Cytokine assay
Supernatants from cultured ovarian cancer cells were stored
at20C for batch analyses to measure cytokines. Supernatants
were evaluated for cytokines/chemokines using the MILLIPLEX
MAP murine cytokine/chemokine panel (Millipore). Cytokine
levels were measured in 50 mL of supernatant by Multiplex
cytometric bead array (Multiplex) assay on a Luminex 100
analyzer (Luminex Corporation). The intervariability for all
inflammatory cytokines tested was less than 10%, indicating
the high reliability of the Multiplex-Luminex method of cyto-
kine assay.
Migration and invasion assays
Modified Boyden chambers (Coster) were coated with 0.1%
gelatin (for migration assays) or extracellular matrix components
(for invasion assays). Untreated, B20-sensitive, and B20-resistant
immortomouse macrophages were suspended in 100 mL of
serum-free media following 1 hour of exposure to B20 and then
added to the upper chamber. Completemedia for cells containing
10% FBS (500 mL) were added to the bottom chamber as a
chemoattractant. The chambers were incubated at 37C in 5%
CO2 for 6 hours (migration) or overnight (invasion). After incu-
bation, cells were fixed, stained, and counted in five random fields
using light microscopy at 200.
Cell viability assay
Immortalized murine macrophages sensitive or resistant to
anti-VEGF therapy (1  104 in 100 mL) were plated in a 96-well
plate. After 24 hours, MTT was added to each well. The plate was
incubated at 37C for 20 minutes, and then absorbance was read
at 570 nm (CERES UV 900C; Bio-Tek Instruments, Inc.).
Immunostaining
All staining was performed in formalin-fixed, paraffin-
embedded 8-mm-thick tumor sections or optimal cutting tem-
perature compound–embedded frozen tissue sections. Follow-
ing deparaffinization, rehydration, and antigen retrieval or
fixation, 3% H2O2 was used to block endogenous peroxidase
activity for 10 minutes. Protein blocking of nonspecific epi-
topes was done using either 5% normal horse serum, 1%
normal goat serum, or 4% fish gelatin in either PBS or TBS-
T (Tris-buffered saline with Tween) for 20 minutes. Slides were
incubated with primary antibody for CD68 (Santa Cruz
Biotechnology; 1:400), VEGFR-1 (Santa Cruz Biotechnology;
1:500), VEGFR-3 (Millipore; 1:300), E-cadherin (BD Transduc-
tion Laboratories; 1:50), vimentin (Cell Signaling Technology;
1:50), cytokeratin wide (Dako; 1:100), or CD31 (BD Pharmin-
gen; 1:800 for mouse tissue) overnight at 4C. For immuno-
histochemistry, after the primary antibody was washed with
PBS, the appropriate amount of horseradish peroxidase–con-
jugated secondary antibody was added and visualized with
3,30-diaminobenzidine chromogen, and counterstaining was
done with Gill's Hematoxylin #3. For immunofluorescence,
secondary antibody staining was performed with Alexa Fluor
594 or 488 (Molecular Probes). Nuclear staining was per-
formed with Hoechst 33342 (Molecular Probes; #H3570;
Dalton et al.
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1:10,000). Light field images were obtained using a Nikon
Microphot-FXA microscope and a Leica DFC320 digital camera
(Leica Camera), and immunofluorescent images were ob-
tained using a Zeiss Axioplan 2 microscope and a Hamamatsu
ORCA-ER digital camera. To quantify microvessel density,
we examined 5 to 10 random fields at 100 magnification
for each tumor (five tumors per group) and counted the micro-
vessels within those fields as previously described (20). A
vessel was defined as an open lumen with at least one adjacent
CD31-positive cell. Multiple positive cells beside a single
lumen were counted as one vessel. Quantification was per-
formed by two investigators in a blinded fashion. Prolifera-
tion indices were determined using CellProfiler 2.0 from three
representative fields at200 magnification for each tumor (five
tumors per group). Ki-67–positive cells per high-power field
were counted.
Patient tumor samples
Costaining of CD68/VEGFR-1 or of CD68/VEGFR-3 was
carried out on paraffin sections obtained from 10 patients
with stage III or IV ovarian cancer. The study was approved
by the MD Anderson Institutional Review Board. Eighty percent
(8/10) of the cases had high-grade serous ovarian cancer, and
the remaining had low-grade serous cancer. All patients were
treated with bevacizumab plus chemotherapy and were then
grouped into responders (complete or partial response) and
nonresponders (stable or progressive disease) based on the
RECIST guidelines version 1.1.
Results
Macrophage levels increase with the emergence of anti-VEGF
therapy resistance
To evaluate the potential role of immune cells in the devel-
opment of resistance to VEGF blockade, we first established a
syngeneic mouse model of adaptive resistance to anti-VEGF
therapy. After intraperitoneal injection of luciferase-labeled
IG10 murine ovarian cancer cells and after confirmation of
tumor establishment with bioluminescence imaging, immune-
competent C57BL/6 mice were randomized to receive (1)
control (placebo) or (2) B20 (murine VEGF-A–targeted mono-
clonal antibody; Genentech Inc.) treatment twice weekly. Both
groups underwent weekly bioluminescence imaging to monitor
tumor growth. Mice receiving B20 were divided into B20-
sensitive and B20-resistant groups, approximately 2 weeks after
the start of treatment on the basis of imaging: B20-resistant
mice were defined as those with increased tumor growth on
treatment, and B20-sensitive mice were defined as responders
to the treatment (Fig. 1A and B). All mice were subsequently
sacrificed and their tumors collected and analyzed. Compared
with the B20-sensitive group, B20-resistant mice had signifi-
cantly higher tumor burden than controls (Fig. 1C and D;
Supplementary Fig. S1A).
Immune profiling was carried out on tumors collected from
control, B20-sensitive, and B20-resistant mice using FACS anal-
ysis. Compared with B20-sensitive mice, macrophage levels
were substantially increased in the tumors of B20-resistant
mice, whereas other immune cell populations remained largely
unchanged (Fig. 1E and F). CD68þ staining of tumor samples
confirmed the increase in macrophage numbers (Fig. 1G and
H). In addition, tumors from B20-resistant mice showed higher
vessel density than either control or B20-sensitive tumors, as
measured by CD31 staining (Fig. 1I and J). The marked increase
in macrophages seen along with increased blood vessel density
in B20-resistant tumors led us to consider macrophages as
potential catalysts in resistance to anti-VEGF therapy.
Depletion of macrophages at the emergence of anti-VEGF
resistance restores sensitivity
We next asked whether depletion of macrophages could
restore sensitivity to anti-VEGF therapy. Bisphosphonates, such
as zoledronic acid and clodronate, are clinically approved for
the treatment of osteoporosis and bony metastases, but also
induce robust macrophage depletion (21–23). Therefore, we
first studied the role of zoledronic acid in anti-VEGF therapy
resistance in C57BL/6 mice bearing IG10 tumors. After biolu-
minescence imaging to confirm the establishment of tumors,
mice were randomized to receive (1) control, (2) B20 only, or
(3) B20 plus zoledronic acid. The control group received
placebo until becoming moribund and these mice were then
sacrificed. The B20-only group received treatment twice weekly
until the emergence of resistance, defined by an increase in
previously stable disease burden on bioluminescence imaging,
and were sacrificed when they became moribund. The B20 plus
zoledronic acid group received B20 alone until resistance
developed; then, weekly zoledronic acid was added to the
B20 regimen. The combined treatment was continued until
mice became moribund and were sacrificed.
Next, we repeated the above experiment in a different mouse
model. In this model, nude mice were injected with luciferase-
labeled OVCAR5 (human ovarian cancer cells) and randomized
to receive (1) control, (2) bevacizumab only, or (3) bevacizumab
plus zoledronic acid. Mice were treated as shown in Fig. 1K. In
both experiments, the addition of zoledronic acid at the emer-
gence of resistance halted tumor growth and significantly pro-
longed survival compared with control or anti-VEGF therapy–
only groups (Fig. 1L andM).Also, immunohistochemical staining
of tumor samples demonstrated significantly lower macrophage
levels in mice receiving B20 plus zoledronic acid (Fig. 1N; Sup-
plementary Fig. S1C) or bevacizumab plus zoledronic acid (Sup-
plementary Fig. S1D and S1E) than in control or anti-VEGF
therapy–only groups.
Macrophage-deficient mice have delayed resistance to anti-
VEGF therapy
We next examined the contribution of macrophages to anti-
VEGF therapy resistance using a murine CSF1R knockout model.
Csf1rfl/fl floxed mutant mice possess loxP sites flanking exon 5 of
the colony-stimulating factor 1 receptor (Csf1r) gene (B6.Cg-Csflr
(tmlJwp)/J). CSF1R–/– mice were injected intraperitoneally with
IG10 cells and randomly assigned to receive (1) control or (2)
B20. As additional controls, matched groups of wild-type C57BL/
6mice were injectedwith IG10 cells and given either no treatment
or B20. Treatments began 21 days after cell inoculation, with B20
given twice weekly. Compared with wild-type mice, CSF1R–/–
mice receiving no treatment had shorter survival, whereas
CSF1R–/–mice receiving B20 failed to develop resistance to VEGF
blockade, as illustrated by their prolonged survival and smaller
tumor burden (Fig. 2A and B). Immunohistochemical staining
confirmed significantly reduced macrophage numbers in
CSF1R–/– groups treated with B20 compared with WT and
CSF1R–/– control groups (Fig. 2C).
Macrophages Adapt to Anti-VEGF Therapy
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Adding macrophages to macrophage-deficient mice induces
anti-VEGF therapy resistance
Next, we investigated whether introduction of macrophages
into our CSF1R–/– model would restore the wild-type pattern
of anti-VEGF therapy resistance. CSF1R–/– mice were injected
with IG10 cells and assigned to receive (1) B20 alone or (2)
B20 plus macrophage transfusion. As controls, matched groups
of wild-type C57BL/6 mice were also injected with IG10 cells
and treated with B20 alone or B20 plus macrophages. Treat-
ments and macrophage infusion began 21 days after cell
inoculation to allow for established disease; B20 treatment
was given twice weekly. For macrophage infusion, macro-
phages (5  105) were injected intravenously once weekly
until they become moribund. Consistent with our results
noted above, the survival of CSF1R–/– mice receiving macro-
phage infusion with B20 recapitulated that of the untreated
wild-type mice (Fig. 2D). CSF1R–/– mice treated with B20
alone again failed to develop resistance, whereas all wild-type
mice receiving B20 developed resistance following an initial
period of sensitivity (Fig. 2D and E). Compared with CSF1R–/–
mice treated with B20 alone, CSF1R–/– mice receiving macro-
phage infusions had tumors with significantly increased
macrophage infiltration on immunohistochemical and FACS
analyses (Fig. 2F; Supplementary Fig. S2A).
Macrophages with resistance to anti-VEGF therapy are
recruited to the tumor microenvironment
Considering the substantial increase in tumor-associated
macrophages at the emergence of resistance, as well as recent
data suggesting that both resident macrophages and bone mar-
row–derived macrophages can proliferate (24), we next consid-
ered the origin ofmacrophages that become enriched in the tumor
microenvironment with adaptive resistance. Specifically, we
investigated whether the increase in macrophages seen at the
emergence of resistance was secondary to resident macrophage
proliferation or to increased recruitment from bone marrow
populations. Bone marrow was isolated from GFP-labeled FVB.
Cg-Tg(CAG-EGFP)B5Nagy/J mice (bone marrow donor mice).
These mice express GFP in all tissues, including the bone marrow
and its derived cells. Following cell sorting to isolate GFP-high
expressing cells, the sorted bonemarrow donor cells were injected
into irradiated (to deplete existing bone marrow) wild-type
C57BL/6 recipient mice (n ¼ 15). Successful bone marrow trans-
plantation was confirmed by hematologic profiling 3 weeks after
transplant, including verification of GFP expression in bone
marrow–derived cells (Fig. 2G). Mice were then injected with
luciferase-labeled IG10 cells 4 weeks after transplant. Biolumi-
nescence imaging confirmed tumor establishment 21 days after
injection of IG10 cells. Three mice were sacrificed, and their
tumors harvested to establish baseline characteristics of tumor
macrophages. The remaining mice (n ¼ 12) received B20 treat-
ment twice weekly and had weekly bioluminescence imaging.
Three of these mice were sacrificed and their tumors harvested
while they still showed sensitivity to anti-VEGF therapy, as dem-
onstrated by imaging. B20 treatment continued in the remaining
mice until resistance to therapy emerged. The mice were then
sacrificed, and their tumors were harvested.
In the harvested tumors, macrophages were assessed by immu-
nofluorescence. Bone marrow–derived macrophages were iden-
tified by dual expression of GFP and F4/80. In contrast, the
resident tissue macrophages were not affected by bone marrow
transplant and therefore expressedonly F4/80, notGFP.We found
that >90% macrophages in resistant tumors were bone marrow
derived (Fig. 2H). We also assessed VEGFR-1 expression in the
macrophages recruited to the tumor microenvironment with
adaptive resistance to anti-VEGF antibody (AVA). Most of the
VEGFR-1–negative macrophages were recruited from the bone
marrow (Supplementary Fig. S2B).
Macrophage depletion increases the effectiveness of
anti-VEGF therapy
In light of our data implicating macrophages in the devel-
opment of resistance to VEGF blockade, we examined the
upfront combination of macrophage depletion with AVA. To
investigate resistance to bevacizumab, nude mice were injected
with either SKOV3ip1 or OVCAR5 (human ovarian cancer cell
lines) and then randomly assigned to receive (1) no treatment,
(2) bevacizumab only, (3) zoledronic acid only, or (4) beva-
cizumab plus zoledronic acid. The mice were sacrificed and their
tumors harvested when the mice in any group became mori-
bund. The group treated with bevacizumab plus zoledronic acid
had significantly reduced tumor weight and fewer nodules in
both the SKOV3ip1 (Fig. 3A) and OVCAR5 (Fig. 3B) models
compared with the other groups. We tested these results for
consistency using a second bisphosphonate, clodronate, in the
SKOV3ip1 model (Supplementary Fig. S3A and S3B). The
combination groups using bevacizumab plus either zoledronic
acid (Fig. 3C and D) or clodronate (Supplementary Fig. S3C
Figure 1.
Macrophage levels increase with the emergence of anti-VEGF therapy resistance. A, C57BL/6 mice that received intraperitoneal injections of IG10 murine
ovarian cancer cells were randomly assigned to one of two groups (control or B20 treatment). The control group received placebo until becoming
moribund and were then sacrificed. The B20-only group received treatment twice weekly until the emergence of resistance, defined by an increase in
previously stable disease burden on bioluminescence imaging, and were sacrificed when they became moribund. Bioluminescence imaging was performed
once weekly. The color scale bars depicting the photon fluxes emitted from the tumor cells are shown. B, Quantitative representation of bioluminescence. C,
Bar graph shows the average tumor weight (D) and ascites. E, Immune profiling of tumors from B20-sensitive and -resistant tumors. F, Quantitative
representation of CD11bþ/F4/80þ macrophages. G, Representative immunohistochemical images of B20-sensitive and -resistant tumors with CD68
expression. Scale bars, 100 mm. H, Quantitative representation of macrophage levels in B20-sensitive and -resistant tumors. I, CD31 antibody staining of
sections of the B20-sensitive and -resistant tumors. Scale bars, 100 mm. J, Quantitative representations of blood vessel count in both groups. K,
Schematic representation of the experimental setup. L, The impact of B20 and zoledronic acid treatment on survival in mice. Mice bearing IG10 tumors
were treated with control, B20, or B20 plus zoledronic acid (Zol). A Kaplan–Meier curve was used to analyze the survival difference between control and
treatment groups (n ¼ 10). M, The above experiment was repeated using human ovarian cancer line OVCAR5. A Kaplan–Meier curve was used to analyze
the survival difference between control and treatment groups (n ¼ 10). N, Representative immunohistochemical images of IG10 tumor sections
following control, B20, or B20 plus zoledronic acid treatment. The sections were stained using CD68 antibody. Scale bars, 100 mm. Mean  SEM values
are shown.  , P < 0.001 and  , P < 0.0001.
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Figure 2.
Macrophage-deficientmice donot develop resistance to anti-VEGF therapy.A,WTandCSF1R–/–micewere injected intraperitoneallywith IG10 cells. Thesemicewere
assigned to 4 groups (10 mice/group): group 1 WTmice treated with control antibody, group 2 wasWTmice received the B20 antibody, group 3 was CSF1R–/–mice
administered control antibody, and group 4 was CSF1R–/– mice treated with the B20 antibody. A Kaplan–Meier curve was used to analyze the survival difference
between control and treatment groups. B, Representative images of the extent of metastatic spread in both WT and CSF1R–/– mice following control vs. B20
treatment. Metastatic areas are outlined with dotted white lines. C, Immunohistochemical staining using CD68 antibody on control or B20-treated tumor
sections fromWT and CSF1R–/–mice. Scale bars, 100mm. Bar graph represents the quantification of macrophage expression.D,WT and CSF1R–/–mice were injected
intraperitoneally with IG10 cells and were assigned to 4 groups (10 mice/group): groups 1 and 2 were WT mice treated with either B20 alone or with injection
of B20þ macrophages. Groups 3 and 4 were CSF1R–/– mice following B20 alone or with injection of B20þ macrophages. A Kaplan–Meier curve was used to
analyze the survival difference between control and treatment groups. E, Representative images of the extent of metastatic spread in both WT and CSF1R–/– mice
following B20 treatment with or without macrophage injection. Metastatic areas are outlined with dotted white lines. F, Immunohistochemical staining using
CD68 antibody following B20 treatment with or without macrophage injected tumor sections from both WT and CSF1R–/– mice. Scale bars, 100mm. Bar graph
represents the quantification of macrophage expression. G, Schematic representation of experimental setup. H, Bone marrow was isolated from GFP-labeled FVB.
Cg-Tg(CAG-EGFP)B5Nagy/J donor mice and injected into irradiated WT recipient mice following B20 treatment. Representative images of immunofluorescence
staining of F4/80 and GFP on B20-sensitive and -resistant tumor sections. Scale bars, 100 mm. Mean  SEM values are shown.  , P < 0.0001.
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and S3D) demonstrated significantly fewer macrophages than
the other groups did. This decrease in macrophage infiltration in
the combination groups mirrors the results seen in anti-VEGF
therapy–sensitive tumors in our initial immune profiling
(Fig. 1E and F; Supplementary Fig. S1B). We also checked for
polarization status of infiltrating macrophages in the group of
mice showing anti-VEGF resistance. We found that infiltrating
macrophages in resistant groups were positive for CXCL 9 and
CXCL 10 (M1 macrophage chemokine receptors), whereas there
was no colocalization with F4/80 and MR (mannose receptor;
marker for M2 macrophage population) expression (Supple-
mentary Fig. S3E).
Anti-VEGF therapy–resistant macrophages have heightened
viability, migration, and invasion
To identify potential differences between AVA-sensitive
and -resistant macrophages that might contribute to resis-
tance, we compared the cell viability of these macrophages
using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) assay. After exposure to either 2 weeks (to
reflect the anti-VEGF therapy–sensitive condition) or 6 weeks
(to reflect the AVA-resistant condition) of B20 treatment,
murine macrophages were exposed to MTT, and cell viability
was assessed. Compared with sensitive macrophages, resistant
macrophages demonstrated a 73% increase in cell viability
(Supplementary Fig. S4A). In addition, we assessed apoptosis
in AVA-sensitive and -resistant macrophages. Resistant
macrophages displayed significantly increased resistance to
apoptosis following exposure to paclitaxel (Supplementary
Fig. S4B).
On the basis of the increased recruitment of macrophages at
the emergence of resistance, we investigated differences in the
ability of AVA-sensitive and -resistant macrophages to invade
and migrate following exposure to an anti-VEGF drug. Both
groups of macrophages were exposed to B20 for 1 hour and
then plated into modified Boyden chambers. Migration and
invasion were subsequently assessed at 6 and 24 hours, respec-
tively. As predicted, sensitive macrophages displayed signifi-
cantly inhibited migration and invasion following exposure to
B20. In contrast, the ability of resistant macrophages to
migrate and invade was not affected by exposure to B20
(Supplementary Fig. S4C and S4D).
Anti-VEGF therapy–resistant macrophages express low
VEGFR and secrete alternative proangiogenic cytokines
To assess phenotypic differences between AVA-sensitive
and -resistant macrophages, we performed a cytokine array.
Supernatant was collected from murine macrophages exposed
to either 2 weeks (sensitive) or 6 weeks (resistant) of B20
treatment and evaluated for cytokines/chemokines using
the MILLIPLEX MAP murine cytokine/chemokine panel (Milli-
pore). Compared with sensitive macrophages, resistant
Figure 3.
Macrophage depletion increases the effectiveness of anti-VEGF therapy. A, Nude mice were injected with SKOV3ip1 tumor cells into the peritoneal cavity
followed by bevacizumab and zoledronic acid treatment. At the end of the study, mice were euthanized, tumors were harvested, and average tumor
weight and number of nodules is shown. B, Aggregate mass of intraperitoneal implanted OVCAR5 tumor and number of nodules followed by bevacizumab
and zoledronic acid treatment. C, Immunohistochemical staining using CD68 antibody on bevacizumab and zoledronic acid treated on SKOV3ip1 tumor
sections. Scale bars, 100 mm. Bar graph represents the quantification of CD68þ staining. D, Representative images and quantification of CD68 staining
on OVCAR5-induced tumor followed by bevacizumab and zoledronic acid treatment. Mean  SEM values are shown. Control vs. combination  , P < 0.05;
 , P < 0.001; and  , P < 0.0001.
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macrophages secreted significantly less VEGF and instead
showed increased secretion of alternative proangiogenic cyto-
kines and chemokines, including PDGF and G-CSF (Fig. 4A).
Concurrently, we compared macrophage populations in the
sensitive and resistant conditions using RPPA. Immortalized
murine macrophages were harvested and protein extracted
Figure 4.
Anti-VEGF therapy–resistant macrophages express alternate proangiogenic cytokines. A, Cytokine array using supernatant from bevacizumab (Bev) sensitive
and resistant macrophages. B, Heat map represents normalized protein expression levels obtained from the RPPA array using sensitive and resistant
macrophages. C, Pathway analysis of RPPA array. D, Netwalker analysis of RPPA data between sensitive and resistant macrophages. E, Heat map represents
normalized gene expression levels obtained from the mRNA array between sensitive and resistant macrophages. F, Netwalker analysis of gene
expression between sensitive and resistant macrophages. Mean  SEM values are shown.  , P < 0.05 and  , P < 0.001.
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following 2 weeks (sensitive) or 6 weeks (resistant) of treatment
with B20 in vitro. Pathway analysis again demonstrated that the
VEGFR-interacting network is downregulated in the resistant
population (Fig. 4B–D; Supplementary Fig. S4E).
Considering the significant differences inmacrophage numbers
in the AVA-sensitive and -resistant settings, we investigated the
genotypic differences between these populations. Immortalized
murine macrophages were cultured in vitro and treated with B20
twice weekly. Macrophages were collected at 2 weeks (sensitive)
and 6 weeks (resistant), and gene expression profiling was per-
formed on isolated RNA. Analysis of these data revealed signif-
icant downregulation of the VEGF pathway and upregulation of
Figure 5.
Anti-VEGFR expression on macrophages correlates with clinical outcome of anti-VEGF therapy, and anti-VEGF therapy–resistant macrophages shows
methylation on VEGFR promoters. Downregulation of VEGFR-1 (A) and VEGFR-3 (B) mRNA in the setting of anti-VEGF therapy resistance. C,
Immunofluorescence staining of macrophage VEGFR-1 and VEGFR-3 expression following treatment with B20 in sensitive and resistant macrophages.
Scale bars, 20 mm. Representative images of macrophage expression of (D) VEGFR-1 in B20-sensitive and B20-resistant tumors. E, Bar graph
represents the percentage of VEGFR-1–expressing macrophages in B20-sensitive and -resistant tumors. F, Representative images of VEGFR-3–expressing
macrophages in B20-sensitive and -resistant tumors. Scale bars, 100 mm. G, Percentage of VEGFR-3–expressing macrophages in B20-sensitive and
-resistant tumors. H, VEGFR-1 CPG methylation by methylation-specific polymerase chain reaction (MSP). I, VEGFR-3 CPG methylation by MSP.
Mean  SEM values are shown.  , P < 0.05;  , P < 0.01; and  , P < 0.001.
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alternative proangiogenic pathways in resistant macrophages
compared with sensitive macrophages (Fig. 4E and F).
VEGFR expression is decreased, and VEGFR promoters are
methylated in anti-VEGF therapy–resistant macrophages
On the basis of the downregulation of VEGF receptors
seen in the gene expression profiling of resistant macrophages,
we assessed VEGFR expression on macrophages in vitro. Cul-
tured immortalized murine macrophages were treated with
B20 twice weekly. VEGFR expression was assessed by qPCR at
baseline as a control, 2 weeks (sensitive), and 6 weeks (resis-
tant). We found that following an initial period of upregula-
tion during the AVA-sensitive phase, VEGFR-1 and VEGFR-3
expressions were significantly downregulated in the setting of
anti-VEGF therapy resistance at both RNA (Fig. 5A and B) and
VEGFR-1 protein expression (Supplementary Fig. S5A). These
results were confirmed by immunofluorescence staining
(Fig. 5C). In parallel, we assessed colocalization of CD68, a
macrophage marker, and of VEGFR-1 and VEGFR-3 from in vivo
AVA-sensitive and -resistant tumor samples. Again, we noted
less macrophage expression of VEGFR-1 (Fig. 5D and E) and
VEGFR-3 (Fig. 5F and G) in resistant tumors than in sensitive
tumors.
Figure 6
VEGFR expression on macrophages correlates with clinical outcome. A, Immunofluorescence staining of macrophages along VEGFR-1 expression
following anti-VEGF therapy in patient samples (5 samples/group). B, Bar graph represents the VEGFR-1–expressing macrophages. C,
Immunofluorescence staining of macrophages along VEGFR-3 expression following anti-VEGF therapy in patient samples. D, Bar graph represents
the VEGFR-1–expressing macrophages. Scale bars, 20 mm. E, Schematic representation of a hypothetical model. Mean  SEM values are shown.
 , P < 0.001.
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We next sought to uncover the mechanism of macro-
phage VEGFR-1 and VEGFR-3 downregulation. We investigat-
ed changes in transcription, translation, and protein stability
between sensitive and resistant states and found that transcrip-
tion alterations predominated. To further explore the mechan-
isms responsible for these changes, we assessed methylation
of the promoter regions of VEGFR-1 and VEGFR-3. DNA
samples from AVA-sensitive and -resistant immortalized
murine macrophages were treated with bisulfite, and methyl-
ation-specific polymerase chain reaction (MSP) analysis was
performed, revealing a significant increase in methylation at
the VEGFR-1 and VEGFR-3 promoter regions in resistant
macrophages (Fig. 5H and I).
To test the biological consequences of macrophages based
on VEGFR expression, we treated established SKOV3ip1 tumors
with VEGFR-1–positive or –negative macrophages along with
AVA and evaluated tumor burden. Tumors injected with
VEGFR-1–positive macrophages responded to AVA, whereas
those injected with VEGFR-1–negative macrophages continued
to grow (Supplementary Fig. S5B).
VEGFR expression on macrophages correlates with clinical
outcome of anti-VEGF therapy
Next, we investigated the role of macrophage VEGFR
expression on anti-VEGF therapy–resistant ovarian cancer in
patients. Using patient data, we assessed pretreatment mac-
rophage VEGFR expression as a possible predictor of response
to anti-VEGF therapy. Paraffin sections from pretreatment
ovarian cancer biopsy specimens (5 samples in each case)
were stained for CD68 and VEGFR expression. Macrophage
VEGFR expression was then correlated with clinical response
to anti-VEGF therapy. We observed a trend of low macrophage
VEGFR expression in nonresponders against anti-VEGF ther-
apy (Fig. 6A–D). Figure 6E shows a schematic representation
of the model to reflect the findings from this article.
Discussion
In the current study, we demonstrate a previously unrecog-
nized role of macrophages in resistance to VEGF blockade.
These macrophages are actively recruited to the tumor micro-
environment from the bone marrow, where their accumulation
correlates with the emergence of anti-VEGF therapy resistance.
The downregulation of VEGFR-1 and VEGFR-3 accompanies
upregulation of alternative angiogenic pathways, facilitating
escape from VEGF-directed therapies.
Importantly, the depletion of macrophages using bispho-
sphonates at the emergence of anti-VEGF therapy resistance
halted tumor growth and prolonged survival in our murine
model. We show that bisphosphonates plus anti-VEGF ther-
apy can prevent the development of resistance and improve
the effectiveness of antiangiogenic therapy. These findings
offer direct support to previous clinical observations that
bisphosphonates reduce bone metastasis in patients with
breast cancer and in those with prostate or renal cell carcino-
ma and pre-existing bone metastasis, resulting in a trend
toward increased survival (25, 26). Also, we demonstrate
modulation of macrophage VEGFR in response to anti-VEGF
therapy, with significant VEGFR downregulation in resistant
tumors. This expression of VEGFR is dynamic and reflects
changes at the level of the tumor microenvironment in
response to VEGF blockade. In patient samples, we show that
macrophage VEGFR expression may predict response to anti-
angiogenic therapy.
Our study has important clinical implications. In light of the
role of macrophages in resistance to VEGF blockade, strategies to
modify macrophage response should be investigated in combi-
nation with anti-VEGF therapy. Possible approaches include
bisphosphonates, as described here (e.g., CSF-1 or CCR2 inhibi-
tors, and trabectedin; refs. 27–29). The upfront combination of
these therapies with VEGF blockade could be considered for
diminishing the opportunity of macrophages to contribute to
anti-VEGF therapy resistance. In addition, macrophage VEGFR
expression offers potential as a predictor of response to anti-VEGF
therapy and may serve as a testable measure of resistance in
patients receiving antiangiogenic therapy.
In summary, we reveal a previously unrecognized role
of macrophages in resistance to anti-VEGF therapy. Macrophage
depletion could be used to improve the effectiveness of VEGF
blockade. Macrophage VEGFR expression may be a predictor of
response to antiangiogenic therapy. These readily translatable
findings warrant further clinical investigation.
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